Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Goodwill & Intangibles: 2021-2025

Historic Goodwill & Intangibles for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to $5.5 million.

  • Rhythm Pharmaceuticals' Goodwill & Intangibles fell 13.38% to $5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 million, marking a year-over-year decrease of 13.38%. This contributed to the annual value of $6.2 million for FY2024, which is 12.15% down from last year.
  • According to the latest figures from Q3 2025, Rhythm Pharmaceuticals' Goodwill & Intangibles is $5.5 million, which was down 3.72% from $5.7 million recorded in Q2 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Goodwill & Intangibles peaked at $8.5 million during Q1 2022, and registered a low of $4.7 million during Q4 2021.
  • Moreover, its 3-year median value for Goodwill & Intangibles was $6.6 million (2024), whereas its average is $6.6 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Goodwill & Intangibles spiked by 70.54% in 2022, and later declined by 13.38% in 2025.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Goodwill & Intangibles stood at $4.7 million in 2021, then surged by 69.24% to $7.9 million in 2022, then dropped by 10.85% to $7.0 million in 2023, then fell by 12.15% to $6.2 million in 2024, then declined by 13.38% to $5.5 million in 2025.
  • Its last three reported values are $5.5 million in Q3 2025, $5.7 million for Q2 2025, and $6.0 million during Q1 2025.